바이오인

 

Advancing Massachusetts Leadership in the Life Sciences … For Patients

 

 

Impact 2020 Executive Summary

The Vision

To advance Massachusetts’ leadership in the life sciences industry, championing innovation in order to bring value to the global healthcare system and make meaningful impact on patient lives

Four themes dominated discussions during the Impact 2020 strategic assessment. Each one leads to a set of recommendations to ensure the industry’s success into the future:

1) Demonstrating Value: There is a genuine concern across the industry that the intense on reducing healthcare spending will undermine the reward for innovation, elevate the risk for companies and investors, and stymie life sciences research and development.
2) Supporting Company Formation and Sustainability: Without ed, consistent support and attention, life sciences companies, particularly at the seed and Series A levels, will be at risk. Alternative sources of funds may not fill the gap, leading to fewer companies forming and surviving.
3) Opportunities in Life Sciences Information Technology: Massachusetts has an important opportunity to take the lead in developing information-based solutions that increase efficiency and mitigate risk at all levels of the biopharma value chain, from basic research to patient care.
4) Articulating the Patient Focus: The industry appears on the verge of major medical breakthroughs, yet concerns about company formation and reimbursement policies could prevent the benefits of those therapies from getting to patients.

 

 

...(계속)

 

☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다.